Stoke Therapeutics, Inc. $STOK Shares Purchased by BVF Inc. IL

BVF Inc. IL lifted its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 36.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 2,265,674 shares of the company’s stock after buying an additional 608,578 shares during the period. Stoke Therapeutics accounts for approximately 2.4% of BVF Inc. IL’s portfolio, making the stock its 12th largest holding. BVF Inc. IL owned approximately 3.97% of Stoke Therapeutics worth $71,912,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of STOK. Principal Financial Group Inc. purchased a new stake in Stoke Therapeutics during the third quarter valued at about $1,062,000. Vanguard Group Inc. grew its position in Stoke Therapeutics by 7.4% during the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after acquiring an additional 217,616 shares during the period. Baillie Gifford & Co. purchased a new stake in Stoke Therapeutics during the fourth quarter valued at about $7,837,000. Hussman Strategic Advisors Inc. purchased a new stake in Stoke Therapeutics during the fourth quarter valued at about $2,000,000. Finally, Checkpoint Capital L.P. purchased a new stake in Stoke Therapeutics during the third quarter valued at about $4,983,000.

Stoke Therapeutics Price Performance

STOK opened at $30.26 on Thursday. The stock has a market capitalization of $1.88 billion, a PE ratio of -10.77 and a beta of 1.17. The firm’s fifty day moving average price is $32.07 and its 200 day moving average price is $32.35. Stoke Therapeutics, Inc. has a 12-month low of $11.17 and a 12-month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The business had revenue of $6.23 million for the quarter, compared to analysts’ expectations of $6.48 million. On average, equities research analysts forecast that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In other news, insider Barry Ticho sold 1,795 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $30.58, for a total transaction of $54,891.10. Following the transaction, the insider owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. This trade represents a 4.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on STOK. Needham & Company LLC lifted their target price on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Wolfe Research began coverage on shares of Stoke Therapeutics in a report on Monday, February 23rd. They set an “outperform” rating and a $40.00 target price on the stock. Wedbush lifted their target price on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Tuesday, March 17th. Canaccord Genuity Group lifted their target price on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a report on Friday, March 20th. Finally, Wall Street Zen lowered shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Stoke Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $41.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.